Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Axsome Therapeutics stock | 74.29

Own Axsome Therapeutics stock in just a few minutes.


Fact checked

Axsome Therapeutics, Inc is a biotechnology business based in the US. Axsome Therapeutics shares (AXSM) are listed on the NASDAQ and all prices are listed in US Dollars. Axsome Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of USD$2.7 billion.

How to buy shares in Axsome Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Axsome Therapeutics. Find the stock by name or ticker symbol: AXSM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Axsome Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$74.29, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Axsome Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Axsome Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Axsome Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Axsome Therapeutics's share price has had significant negative movement.

Its last market close was USD$74.29, which is 18.48% down on its pre-crash value of USD$91.13 and 109.62% up on the lowest point reached during the March crash when the shares fell as low as USD$35.44.

If you had bought USD$1,000 worth of Axsome Therapeutics shares at the start of February 2020, those shares would have been worth USD$680.64 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$791.19.

Axsome Therapeutics share price

Use our graph to track the performance of AXSM stocks over time.

Axsome Therapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$74.29
52-week range USD$20.48 - USD$109.94
50-day moving average USD$74.8616
200-day moving average USD$77.3999
Wall St. target price USD$146.8
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.374

Buy Axsome Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Axsome Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Axsome Therapeutics price performance over time

Historical closes compared with the close of $74.29 from 2020-11-16

1 week (2020-11-23) 4.75%
1 month (2020-10-30) 12.03%
3 months (2020-08-28) -2.52%
6 months (2020-05-29) -3.49%
1 year (2019-11-29) 88.70%
2 years (2018-11-30) 2,178.83%
3 years (2017-11-30) 1,214.87%
5 years (2015-11-30) 741.34%

Axsome Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -47.56%
Return on equity TTM -106.15%
Profit margin 0%
Book value $4.139
Market capitalisation USD$2.7 billion

TTM: trailing 12 months

Shorting Axsome Therapeutics shares

There are currently 3.8 million Axsome Therapeutics shares held short by investors – that's known as Axsome Therapeutics's "short interest". This figure is 4.1% up from 3.7 million last month.

There are a few different ways that this level of interest in shorting Axsome Therapeutics shares can be evaluated.

Axsome Therapeutics's "short interest ratio" (SIR)

Axsome Therapeutics's "short interest ratio" (SIR) is the quantity of Axsome Therapeutics shares currently shorted divided by the average quantity of Axsome Therapeutics shares traded daily (recently around 532323.25905292). Axsome Therapeutics's SIR currently stands at 7.18. In other words for every 100,000 Axsome Therapeutics shares traded daily on the market, roughly 7180 shares are currently held short.

However Axsome Therapeutics's short interest can also be evaluated against the total number of Axsome Therapeutics shares, or, against the total number of tradable Axsome Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Axsome Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Axsome Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1316% of the tradable shares (for every 100,000 tradable Axsome Therapeutics shares, roughly 132 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Axsome Therapeutics.

Find out more about how you can short Axsome Therapeutics stock.

Axsome Therapeutics share dividends

We're not expecting Axsome Therapeutics to pay a dividend over the next 12 months.

Axsome Therapeutics share price volatility

Over the last 12 months, Axsome Therapeutics's shares have ranged in value from as little as $20.48 up to $109.94. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axsome Therapeutics's is 2.8075. This would suggest that Axsome Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Axsome Therapeutics overview

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site